Phagenesis Inc.

Phagenesis Limited is a UK-based MedTech company specializing in innovative neurostimulation treatments for neurogenic dysphagia (swallowing dysfunction) caused by neurological damage, particularly post-stroke. Founded in 2007 by Dr. Conor Mulrooney and Professor Shaheen Hamdy, the company develops the Phagenyx® Neurostimulation System, which uses pharyngeal electrical stimulation (PES) to restore the brain's neural control of swallowing function. The non-invasive device is designed for rapid bedside intervention in acute care settings, enabling early treatment without disrupting clinical workflow—even for critically ill patients. Clinical evidence demonstrates that Phagenyx improves swallowing safety by 2x, reduces time to oral nutrition by 6 days (58% reduction), shortens hospital length of stay by 8 days (37% reduction), and reduces ICU stay by 5 days (64% reduction). The technology addresses a significant clinical need: approximately 45% of stroke survivors experience persistent dysphagia, which increases pneumonia risk 3-fold, PEG tube dependency 5-fold, and mortality 8-fold. Phagenesis is backed by 30+ peer-reviewed publications and recently secured $42 million in Series D funding. The company is now recognized in the 2026 American Heart Association/American Stroke Association guidelines as a recommended tool for post-stroke dysphagia management.